216 related articles for article (PubMed ID: 35306447)
1. Evolution of germline TP53 variant classification in children with cancer.
Tallis E; Scollon S; Ritter DI; Plon SE
Cancer Genet; 2022 Jun; 264-265():29-32. PubMed ID: 35306447
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
3. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
Fortuno C; Lee K; Olivier M; Pesaran T; Mai PL; de Andrade KC; Attardi LD; Crowley S; Evans DG; Feng BJ; Foreman AKM; Frone MN; Huether R; James PA; McGoldrick K; Mester J; Seifert BA; Slavin TP; Witkowski L; Zhang L; Plon SE; Spurdle AB; Savage SA;
Hum Mutat; 2021 Mar; 42(3):223-236. PubMed ID: 33300245
[TBL] [Abstract][Full Text] [Related]
4.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
5. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling.
Bittar CM; Vieira IA; Sabato CS; Andreis TF; Alemar B; Artigalás O; Galvão HCR; Macedo GS; Palmero EI; Ashton-Prolla P
Fam Cancer; 2019 Oct; 18(4):451-456. PubMed ID: 31321604
[TBL] [Abstract][Full Text] [Related]
6. Optimising clinical care through
Luo X; Maciaszek JL; Thompson BA; Leong HS; Dixon K; Sousa S; Anderson M; Roberts ME; Lee K; Spurdle AB; Mensenkamp AR; Brannan T; Pardo C; Zhang L; Pesaran T; Wei S; Fasaye GA; Kesserwan C; Shirts BH; Davis JL; Oliveira C; Plon SE; Schrader KA; Karam R;
J Med Genet; 2023 Jun; 60(6):568-575. PubMed ID: 36600593
[TBL] [Abstract][Full Text] [Related]
7. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
[TBL] [Abstract][Full Text] [Related]
9. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
10. Challenging interpretation of germline TP53 variants based on the experience of a national comprehensive cancer centre.
Butz H; Bozsik A; Grolmusz V; Szőcs E; Papp J; Patócs A
Sci Rep; 2023 Aug; 13(1):14259. PubMed ID: 37653074
[TBL] [Abstract][Full Text] [Related]
11. Specifications of the ACMG/AMP Variant Classification Guidelines for Germline
Hatton JN; Frone MN; Cox HC; Crowley SB; Hiraki S; Yokoyama NN; Abul-Husn NS; Amatruda JF; Anderson MJ; Bofill-De Ros X; Carr AG; Chao EC; Chen KS; Gu S; Higgs C; Machado J; Ritter D; Schultz KA; Soper ER; Wu MK; Mester JL; Kim J; Foulkes WD; Witkowski L; Stewart DR
Hum Mutat; 2023; 2023():. PubMed ID: 38084291
[TBL] [Abstract][Full Text] [Related]
12. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
13. Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey.
Rippinger N; Fischer C; Haun MW; Rhiem K; Grill S; Kiechle M; Cremer FW; Kast K; Nguyen HP; Ditsch N; Kratz CP; Vogel J; Speiser D; Hettmer S; Glimm H; Fröhling S; Jäger D; Seitz S; Hahne A; Maatouk I; Sutter C; Schmutzler RK; Dikow N; Schott S
Cancer; 2020 Sep; 126(17):4032-4041. PubMed ID: 32557628
[TBL] [Abstract][Full Text] [Related]
14. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
15. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
[TBL] [Abstract][Full Text] [Related]
16. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Discordant Variant Interpretations in a Large Family-Based Study of Li-Fraumeni Syndrome.
Frone MN; Stewart DR; Savage SA; Khincha PP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34805717
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
19. Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
Shaul E; Roth M; Lo Y; Geller DS; Hoang B; Yang R; Malkin D; Gorlick R; Gill J
Cancer; 2018 Mar; 124(6):1242-1250. PubMed ID: 29313943
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of
Schwartz AN; Hyman SR; Stokes SM; Castillo D; Tung NM; Weitzel JN; Rana HQ; Garber JE
JCO Precis Oncol; 2021 Nov; 5():1677-1686. PubMed ID: 34994652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
